Literature DB >> 18405881

Treatment of lung cancer cells with cytotoxic levels of sodium selenite: effects on the thioredoxin system.

Markus Selenius1, Aristi Potamitou Fernandes, Ola Brodin, Mikael Björnstedt, Anna-Klara Rundlöf.   

Abstract

Selenium at subtoxic doses has been shown to have tumor specific cytotoxic effects. In this work, viability measurements in different lung cancer cell lines showed that selenite was more effective compared to three different conventional cytotoxic drugs. In addition, the cell line most sensitive to selenite toxicity comprised the highest level of thioredoxin reductase 1 (TrxR1). The human selenoenzyme TrxR1 is a central enzyme for cell growth, differentiation, and the protection against oxidative stress. TrxR1, which in several studies has been shown to be up-regulated in various tumor cells, is also a target for many anticancer drugs. In this study, inhibition of TrxR resulted in enhanced selenite cytotoxicity, clearly connecting the thioredoxin system to the toxic effects mediated by selenite. The complex regulation of TrxR1, involving the expression of many different transcript forms of mRNA, was investigated by real-time qPCR in lung cancer cell lines following treatment with toxic doses (2.5-10 microM) of sodium selenite. Selenium treatment resulted in increased expression of almost all TrxR1 mRNA variants with increasing concentrations of selenite. On the contrary, the TrxR protein level and activity, increased at low to moderate doses followed by a decrease at higher doses, indicating impairment of protein synthesis by selenite.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18405881     DOI: 10.1016/j.bcp.2008.02.028

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  8 in total

Review 1.  Thioredoxin and thioredoxin target proteins: from molecular mechanisms to functional significance.

Authors:  Samuel Lee; Soo Min Kim; Richard T Lee
Journal:  Antioxid Redox Signal       Date:  2012-06-26       Impact factor: 8.401

2.  Treatments with sodium selenate or doxycycline offset diabetes-induced perturbations of thioredoxin-1 levels and antioxidant capacity.

Authors:  Mustafa Atalay; Ayca Bilginoglu; Tarja Kokkola; Niku Oksala; Belma Turan
Journal:  Mol Cell Biochem       Date:  2011-01-19       Impact factor: 3.396

3.  Augmented antitumor effects of combination therapy of cisplatin with ethaselen as a novel thioredoxin reductase inhibitor on human A549 cell in vivo.

Authors:  Qiang Tan; Jing Li; Han-wei Yin; Li-hui Wang; Wan-chen Tang; Fang Zhao; Xin-min Liu; Hui-hui Zeng
Journal:  Invest New Drugs       Date:  2009-03-07       Impact factor: 3.850

4.  Extracellular thiol-assisted selenium uptake dependent on the x(c)- cystine transporter explains the cancer-specific cytotoxicity of selenite.

Authors:  Eric Olm; Aristi P Fernandes; Christina Hebert; Anna-Klara Rundlöf; Erik H Larsen; Olof Danielsson; Mikael Björnstedt
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-22       Impact factor: 11.205

Review 5.  Encapsulated nanoepigallocatechin-3-gallate and elemental selenium nanoparticles as paradigms for nanochemoprevention.

Authors:  Dongxu Wang; Ethan Will Taylor; Yijun Wang; Xiaochun Wan; Jinsong Zhang
Journal:  Int J Nanomedicine       Date:  2012-03-29

6.  Biomarkers of selenium status in dogs.

Authors:  Mariëlle van Zelst; Myriam Hesta; Kerry Gray; Ruth Staunton; Gijs Du Laing; Geert P J Janssens
Journal:  BMC Vet Res       Date:  2016-01-19       Impact factor: 2.741

7.  Enhancement of auranofin-induced apoptosis in MCF-7 human breast cells by selenocystine, a synergistic inhibitor of thioredoxin reductase.

Authors:  Chaoran Liu; Zhong Liu; Meng Li; Xiaoling Li; Yum-Shing Wong; Sai-Ming Ngai; Wenjie Zheng; Yibo Zhang; Tianfeng Chen
Journal:  PLoS One       Date:  2013-01-14       Impact factor: 3.240

8.  The Combination of α-Tocopheryl Succinate and Sodium Selenite on Breast Cancer: A Merit or a Demerit?

Authors:  Doaa M Badr; Hafez F Hafez; Azza M Agha; Samia A Shouman
Journal:  Oxid Med Cell Longev       Date:  2016-03-29       Impact factor: 6.543

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.